Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vivo endothelial interaction between ACE and COX inhibitors.

R J Gryglewski1, S Chlopicki, J Swies

  • 1Jagiellonian Medical Research Centre, Department of Experimental Pharmacology, Jagiellonian University, Poland 17 Slawkowska, 31-016 Cracow, Poland. mfgrygle@cyf-kr.edu.pl

Prostaglandins, Leukotrienes, and Essential Fatty Acids
|January 1, 2005
PubMed
Summary

This study examines how blood pressure medications called ACE inhibitors trigger the breakdown of blood clots in rats. The researchers found that these drugs work by stimulating the release of protective substances from blood vessel linings, specifically involving a protein called COX-2. Understanding this interaction helps clarify why certain anti-inflammatory drugs might interfere with the clot-dissolving benefits of these heart medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelium- selective overexpression of p25 results in impaired smooth muscle-dependent vascular function, altered sGC-dependent pathway, and vascular remodeling.

Vascular pharmacology·2026
Same author

Vascular ATGL-dependent lipolysis and the activation of cPLA<sub>2</sub>-PGI<sub>2</sub> pathway protect against postprandial endothelial dysfunction.

Cellular and molecular life sciences : CMLS·2024
Same author

Aromatic sulphonamides of aziridine-2-carboxylic acid derivatives as novel PDIA1 and PDIA3 inhibitors.

Journal of enzyme inhibition and medicinal chemistry·2023
Same author

Preservation of left ventricle peak and mean pulse flow blood velocity despite progressive deterioration of cardiac function in a chronic heart failure murine model.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2022
Same author

Corrigendum to: Fall in the ATP levels in the red blood cells in ApoE-LDLR double-deficient mice model prior to atherosclerosis development.

European heart journal·2021
Same author

Characterization of age-dependent decline in spontaneous running performance in the heart failure Tgα<sub>q</sub>*44 mice.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2021

Area of Science:

  • Cardiovascular pharmacology and ACE-I therapeutic mechanisms
  • Endothelial cell biology and vascular physiology

Background:

The precise molecular pathways linking blood pressure regulation to clot dissolution remain poorly defined in clinical settings. Prior research has shown that cardiovascular medications influence vascular health beyond their primary effects on systemic pressure. That uncertainty drove investigators to examine how specific drug classes interact within the circulatory system. It was already known that endothelial cells release various signaling molecules in response to pharmacological stimuli. No prior work had resolved the specific dependency of thrombolytic responses on cyclooxygenase isoforms in living models. This gap motivated a detailed assessment of how different enzyme inhibitors modulate vascular clot breakdown. Previous studies often focused on isolated cell cultures rather than integrated physiological systems. Researchers required a controlled environment to observe the interplay between enzymatic pathways and clot stability in vivo.

Purpose Of The Study:

The study aims to elucidate the underlying mechanism of the thrombolytic response induced by angiotensin converting enzyme inhibitors in living subjects. Researchers sought to determine how these medications interact with endothelial pathways to influence blood clot stability. They specifically investigated the role of bradykinin and various cyclooxygenase isoforms in this physiological process. The motivation for this work stemmed from the need to understand how cardiovascular drugs affect vascular health beyond blood pressure control. Investigators aimed to clarify why certain anti-inflammatory medications might interfere with the therapeutic benefits of ACE inhibitors. They designed a series of experiments to isolate the contributions of specific enzymes to the observed clot-dissolving effects. This research addresses the uncertainty regarding the interaction between systemic blood pressure management and local vascular signaling. The team intended to provide a clear pharmacological profile of how these agents modulate endothelial function in vivo.

Keywords:
endothelial functionprostacyclin pathwaycardiovascular pharmacologybradykinin signaling

Frequently Asked Questions

The researchers propose that ACE inhibitors trigger thrombolysis by stimulating endothelial COX-2 to produce prostacyclin, a process mediated by endogenous bradykinin. This mechanism remains active even at non-hypotensive doses, distinguishing it from the primary blood pressure-lowering effects of the drugs.

The study utilized a Wistar rat model equipped with extracorporeal circulation to monitor real-time clot dissolution. This setup allowed for the precise intravenous administration of drugs like perindopril and quinapril while measuring arterial levels of specific prostaglandins.

Icatibant was necessary to abolish the thrombolytic effect and the rise in prostacyclin, confirming the role of bradykinin. In contrast, L-NAME, a nitric oxide synthase inhibitor, failed to significantly alter either the clot-dissolving response or the associated prostacyclinemia.

Related Experiment Videos

Main Methods:

The researchers employed an in vivo bioassay system using anesthetized Wistar rats to evaluate drug interactions. They established extracorporeal circulation to monitor real-time changes in clot stability and vascular signaling. The team administered perindopril and quinapril intravenously at non-hypotensive concentrations to induce specific responses. They utilized various pharmacological agents, including L-NAME and icatibant, to probe the involvement of specific signaling pathways. Selective inhibitors for cyclooxygenase-1 and cyclooxygenase-2 were introduced to determine their respective contributions to the observed effects. The investigators measured arterial blood levels of 6-keto-PGF1 alpha, TXB2, and PGE2 to track enzymatic activity. This approach allowed for the systematic comparison of different inhibitor classes on the thrombolytic process. The study design focused on isolating the endothelial contribution to the observed vascular phenomena.

Main Results:

The strongest finding indicates that ACE-I administration produces dose-dependent thrombolysis in the rat model. This effect correlates with a significant rise in arterial 6-keto-PGF1 alpha levels, while TXB2 and PGE2 remain unaffected. Icatibant treatment at 0.1-0.5 mg kg(-1) completely abolishes both the thrombolytic response and the increase in prostacyclin. In contrast, L-NAME at 5 mg kg(-1) shows no significant impact on these specific outcomes. Selective COX-1 inhibitors, such as SC 560, induce transient thrombolysis and slightly enhance the effects of ACE-I. Conversely, selective COX-2 inhibitors, including rofecoxib and celecoxib, prove thrombogenic and negate the thrombolytic benefits. The data demonstrate that ACE-I-induced clot dissolution relies on endogenous bradykinin and endothelial COX-2. These results confirm that prostacyclin derived from COX-2 is the primary mediator of the observed therapeutic response.

Conclusions:

The authors conclude that non-hypotensive doses of angiotensin converting enzyme inhibitors effectively trigger clot dissolution in living bioassay systems. This response relies heavily on the production of endogenous bradykinin and prostacyclin. The findings suggest that endothelial cyclooxygenase-2 activity serves as a primary mediator for this therapeutic effect. Conversely, selective cyclooxygenase-2 inhibitors demonstrate thrombogenic properties that counteract the benefits of these heart medications. The data imply that clinical co-administration of these drug classes warrants caution due to potential interference. The researchers propose that the observed thrombolysis is distinct from systemic blood pressure changes. This synthesis highlights the importance of maintaining endothelial cyclooxygenase-2 function during cardiovascular therapy. The evidence confirms that prostacyclin release is a key requirement for the observed clot-dissolving mechanism.

Prostacyclin, measured as 6-keto-PGF1 alpha, served as a key indicator of endothelial activation. While ACE inhibitors consistently increased these levels, other markers like TXB2 or PGE2 remained unchanged, highlighting the specificity of the prostacyclin pathway.

The researchers observed that selective COX-2 inhibitors like rofecoxib and celecoxib were thrombogenic. This contrasts with COX-1 inhibitors like SC 560, which induced transient thrombolysis and slightly enhanced the effects of ACE inhibitors.

The authors suggest that the interaction between ACE inhibitors and endothelial COX-2 is vital for maintaining vascular patency. They imply that clinicians should be aware that certain anti-inflammatory agents may negate the beneficial clot-dissolving properties of standard blood pressure treatments.